Drugs / GR2301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07647224 | Jun 2026 → Jul 2027 expected | — | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07647237 | Jun 2026 → Jun 2028 expected | vitiligo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR2301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07647237 ↗ |
| Modality | Monoclonal antibody | “IL15 monoclonal antibody” NCT07647224 ↗ |
| Route | Subcutaneous | “multiple subcutaneous injections” NCT07647237 ↗ |
| Target | IL15 | “IL15 monoclonal antibody” NCT07647224 ↗ |